Abstract 12462: Improved Treatment Satisfaction Independent of Stroke and Bleeding Risk Among Patients Transitioned From a Vitamin K Antagonist to Rivaroxaban: A XANTUS-ACTS Analysis
Introduction: The effectiveness, safety and ease of use of rivaroxaban may reduce anticoagulation treatment burden and improve nonvalvular atrial fibrillation (NVAF) patient satisfaction compared to vitamin K antagonists (VKAs).
Objective: To assess consistency in changes in treatment satisfaction among patients transitioned from a VKA to rivaroxaban in routine practice across stroke and bleeding risk subgroups.
Methods: Xarelto on Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation (XANTUS) was a prospective, non-interventional study in patients prescribed rivaroxaban for prevention of stroke in routine practice within 7 European countries and Canada. Patients receiving a VKA 4-weeks prior to the initial XANTUS study visit and switched to rivaroxaban were asked to complete the Anti-Clot Treatment Scale (ACTS). Changes in scores, as recorded during the initial and first follow-up visit at ~3-months (corresponding to a comparison of rivaroxaban vs. prior VKA) for the ACTS Burdens and Benefits scores, were calculated and reported as least squares (LS)-mean differences with standard errors.
Results: After ~3-months’ rivaroxaban treatment, both Burdens and Benefits scores were significantly improved in NVAF patients with prior VKA treatment (Table). Improvements in Burden scores across subgroups were generally consistent (LS-mean difference range, 2.68 to 3.46) with the overall cohort findings. The Benefit score improved in the overall cohort, but was not found to significantly differ in any subgroup (LS-mean difference range, -0.26 to 0.58).
Conclusions: In XANTUS, patients switching from a VKA to rivaroxaban for stroke prevention reported significant improvements in treatment satisfaction. Independent of stroke or bleeding risk, switching to rivaroxaban appears to improve patient treatment satisfaction; mainly due to a perceived lower treatment burden
Author Disclosures: C.I. Coleman: Research Grant; Modest; Bayer Pharma AG, Bayer HealthCare Pharmaceuticals, Janssen Scientific Affairs, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Company, Portola Pharmaceuticals. Consultant/Advisory Board; Modest; Bayer Pharma AG, Bayer HealthCare Pharmaceuticals, Janssen Scientific Affairs, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Company, Portola Pharmaceuticals. S. Haas: Honoraria; Modest; Aspen, Bayer Healthcare, Bristol-Myers Squibb, Daiichi-Sankyo, Pfizer. Consultant/Advisory Board; Modest; Bayer Healthcare, Bristol-Myers Squibb, CSL-Behring, Daiichi-Sankyo, Sanofi. A. Turpie: Speakers Bureau; Modest; Janssen. Consultant/Advisory Board; Modest; Bayer Pharm. S. Kuhls: Employment; Modest; Bayer HealthCare Pharmaceuticals. S. Hess: Employment; Modest; Bayer Healthcare. T. Evers: Employment; Modest; Bayer Pharma AG. P. Amarenco: None. P. Kirchhof: Consultant/Advisory Board; Modest; 3M Medica, MEDA Pharma, AstraZeneca, Bayer Healthcare, Biosense Webster, Boehringer Ingelheim, Daiichi Sankyo, German Cardiac Society, Medtronic, Merck, MSD, Otsuka Pharma, Pfizer/Bristol-Myers Squibb, Sanofi, Servier, Siemens, Takeda. A. Camm: Speakers Bureau; Modest; Bayer, Boehringer Ingelheim, BMS/ Pfizer, Daiichi Sankyo. Consultant/Advisory Board; Modest; Bayer, Boehringer Ingelheim, BMS/ Pfizer, Daiichi Sankyo.
- © 2016 by American Heart Association, Inc.